NexCAR19 (Talikabtagene autoleucel)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for NexCAR19 (Talikabtagene autoleucel), covering 2026-03-30 to 2026-03-30. Get the full timeline:
Most recent: Clinical Trial Update: NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) [Phase 2, Phase 3]